Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and rewarding because that oh-so-familiar routine of meetings, Skype calls, and deadlines has predictably returned. But what can you do? The world keeps spinning no matter how much we push back. So time to get on with it. Please join us for a cup of stimulation — hot buttered rum is our choice today — as we cast about for items of interest. Speaking of which, here are some tidbits. Hope your day goes well…

Four drug companies have a reached a settlement at the last minute to avoid a federal court trial seeking to blame them for fueling the opioid crisis, The Wall Street Journal reports. Among those reaching a deal are Teva Pharmaceutical (TEVA), AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK). The settlements with two Ohio counties put off the federal jury trial for the companies but fall short of a more comprehensive deal currently being negotiated to resolve thousands of opioid lawsuits nationwide.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy